Valence Discovery (“Valence”), an emerging leader in AI-enabled drug design, today announced it has entered into a drug discovery agreement with Repare Therapeutics (“Repare”, Nasdaq: RPTX), a precision oncology company pioneering synthetic lethality to develop novel therapeutics for genetically-defined patient populations. This agreement will combine Valence’s unique expertise in few-shot learning, generative chemistry, and multiparameter optimization with Repare’s expertise in target identification and medicinal chemistry to rapidly optimize drug candidates against multiple potency, selectivity, safety, and pharmacology criteria.
“We broadly sought out a machine learning partner for our proprietary drug discovery and ultimately found the ideal fit in our own backyard,” says Cameron Black, Ph.D., Executive Vice President of Discovery at Repare Therapeutics. “The depth and breadth of the machine learning talent here in Montreal is exceptional, and we are pleased to be initiating this project with the drug design experts at Valence Discovery.”
“As a world-leader in precision oncology, Repare’s team and technologies have the potential to unlock the next generation of precision oncology medicines for patients,” says Daniel Cohen, CEO at Valence. “We look forward to bringing our expertise in AI-enabled drug design to bear on such important challenges in drug discovery.”